The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research… read more.
Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults… read more.
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.
Micronutrient deficiency, whereby levels of vitamins and minerals essential for healthy bodily function are far too low, is common in people with type 2 diabetes, finds a pooled… read more.
Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to… read more.
Neurocrine Biosciences, Inc. announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement,… read more.
Fizzy water might aid weight loss by boosting blood glucose uptake and metabolism—the rate at which the body uses and converts energy—but the effects are so small, drinking… read more.
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have… read more.
Roche announced that the European Medicines Agency has approved Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular… read more.
Millions of people take metformin, a Type 2 diabetes medication that lowers blood sugar. The “wonder drug” has also been shown to slow cancer growth, improve COVID outcomes… read more.
A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests… read more.
Research investigating testing methods for gestational diabetes suggests that over half of pregnant women with the condition are not being diagnosed with the current NHS blood test process,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
